Cover Image

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

Abstract Introduction Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study. We present data from the BE VIVID Japan patient subpopulation. Methods Global...

Full description

Saved in:
Bibliographic Details
Main Authors: Akihiko Asahina (Author), Yukari Okubo (Author), Akimichi Morita (Author), Yayoi Tada (Author), Atsuyuki Igarashi (Author), Richard G. Langley (Author), Delphine Deherder (Author), Mizuho Matano (Author), Veerle Vanvoorden (Author), Maggie Wang (Author), Mamitaro Ohtsuki (Author), Hidemi Nakagawa (Author)
Format: Book
Published: Adis, Springer Healthcare, 2023-01-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items